Top Markets
#1 Black Phoenix Black Phoenix +825.47%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +24.88%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.87%
#4 Prom Prom +20.14%
#5 SAFEcoin SAFEcoin +19.78%
#6 Magma Finance Magma Finance +19.66%
#7 Beam Beam +19.21%
#8 Bless Bless +17.62%
#9 pipedog pipedog +17.24%
#10 YFSX YFSX +16.01%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
IVERIC bio, Inc. IVERIC bio, Inc.

IVERIC bio, Inc.

ISEE
Rank in Stocks #6262
IVERIC bio, Inc. is a biopharmaceutical enterprise focused on identifying and... IVERIC bio, Inc. is a biopharmaceutical enterprise focused on identifying and advancing innovative therapeutic solutions for eye conditions, with a particular emphasis on age-related and rare inherited retinal diseases (IRDs). A cornerstone of its development pipeline is Zimura, an inhibitor targeting complement factor C5. This compound is currently undergoing investigation for geographic atrophy (GA), a severe form of dry age-related macular degeneration (AMD). Zimura's clinical progression includes the GATHER1 trial, which has successfully concluded its Phase 2/3 stage, and the GATHER2 trial, which is presently in Phase 3. The company's portfolio also features STAR (identified as OPH2005), a candidate in Phase 2b clinical trials for addressing Leber congenital amaurosis type 10 (LCA10) and autosomal recessive Stargardt disease (STGD1). Additionally, IVERIC bio is developing IC-500, a high-temperature requirement A serine peptidase 1 protein inhibitor intended for GA and other forms of age-related retinal degeneration. Other programs include IC-100, aimed at rhodopsin-mediated autosomal dominant retinitis pigmentosa, and IC-200, designed for IRDs stemming from mutations in the BEST1 gene. Beyond these active programs, the company has completed several earlier clinical trials: OPH2001, a Phase 1/2a study evaluating various doses of Zimura monotherapy for GA; OPH2000, a Phase 1/2a trial assessing different doses of Zimura combined with Lucentis for wet AMD; OPH2007, which concluded its Phase 2a study for wet AMD; and OPH2002, a Phase 2a trial for idiopathic polypoidal choroidal vasculopathy. In its earlier-stage research and discovery efforts, IVERIC bio is exploring programs such as miniCEP290 for LCA10, miniABCA4 for STGD1, and miniUSH2A for Usher syndrome type 2A-related IRDs. Established in 2007, the company, originally known as Ophthotech Corporation, adopted its current name, IVERIC bio, Inc., in April 2019. Its operations are based in Parsippany, New Jersey.
Share Price
$39.95
Last synced: 2023-07-10
Market Cap
$2.13B
Change (1 day)
0.38%
Change (1 year)
0.00%
Country
US
Trade IVERIC bio, Inc. (ISEE)

Category

Healthcare
Revenue for IVERIC bio, Inc. (ISEE)
Revenue in Aug 2026 TTM: 0
According to IVERIC bio, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for IVERIC bio, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH